La catena delle opzioni mostra i dati chiave delle opzioni azionarie di BiomX a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per BiomX..

BiomX (AMEX:PHGE) Azioni, Catena delle Opzioni

BiomX

BiomX Inc is a clinical-stage microbiome company based in Israel. The company is engaged in developing both natural and engineered phage cocktails designed to target and destroy harmful bacteria that affect the appearance of the skin, as well as harmful bacteria in chronic diseases, such as inflammatory bowel disease, colorectal cancer, and primary sclerosing cholangitis. BX004 is its therapeutic phage product candidate under development for chronic pulmonary infections caused by Pseudomonas aeruginosa, or P. aeruginosa, a main contributor to morbidity and mortality in patients with CF.

BiomX Inc

BiomX Inc Warrants (13/12/2023)

Deutsche Bank analyst Melissa Weathers maintains Entegris (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENTG#NASDAQ">ENTG</a>) with a Buy and lowers the price target from $145 to $115.

News

Price Target

Analyst Ratings

ENTG

Deutsche Bank Maintains Buy on Entegris, Lowers Price Target to $115

Archer-Daniels-Midland Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ADM#NYSE">ADM</a>) shares are <a target="_blank" href="https://www.benzinga.com/premarket" rel="noreferrer noopener">trading lower on Tuesday.</a>
Yesterday, the company reported third-quarter preliminary adjusted earnings per share of $1.09, <a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/b41733821/adm-reports-preliminary-third-quarter-2024-results" rel="noreferrer noopener">compared with street view of $1.25.</a>
The company will restate previously filed fiscal year 2023 Form 10-K and subsequent Forms 10-Q. The company said it has decided to postpone the webcast originally scheduled for November 5 at 9 a.m. Central Time.
The restated filings will include corrections for newly identified errors related to intersegment sales, will reflect the previously-corrected errors, and will provide disclosures applicable to restated segment information.
&#8220;Our third quarter operating results were mixed in a challenging quarter for the business,&#8221; said Chair of the Board and CEO Juan Luciano.
Archer-Daniels-Midland said net earnings are expected to be $18 million, with adjusted net earnings forecasted at $530 million. The company also anticipates a $461 million non-cash charge against GAAP earnings for the third quarter related to its Wilmar equity investment.
&#8220;We are taking the necessary actions to improve performance and drive continued value creation,&#8221; Luciano added.
Also Read: <a target="_blank" href="https://www.benzinga.com/markets/equities/24/11/41736062/boeing-workers-end-seven-week-strike-by-accepting-new-contract-with-major-pay-increases" rel="noreferrer noopener">Boeing Workers End Seven-Week Strike By Accepting New Contract With Major Pay Increases</a>
Ag Services and Oilseeds (AS&amp;O) segment operating profit was $480 million during the third quarter of 2024, down 43% compared to the prior-year quarter. Carbohydrate Solutions segment operating profit was $452 million for the third quarter of 2024, down 3% compared to the prior year period. Nutrition segment operating profit was $105 million for the third quarter of 2024, down 19% compared to the prior year period.
&#8220;While Carbohydrate Solutions achieved strong results, our Ag Services and Oilseeds and Nutrition businesses delivered results below expectations, impacted by softer than expected market conditions and the pace of our planned improvement efforts,&#8221; added Luciano.
Outlook: The company has lowered its 2024 adjusted EPS guidance to a range of $4.50 &#8211; $5.00, down from the previous range of $5.25 &#8211; $6.25, and <a href="https://www.benzinga.com/calendars/guidance">below the $5.23 analyst estimate.</a>
The company&#8217;s revised outlook reflects trends in ADM&#8217;s performance to date, legislative and regulatory policy uncertainties, and ongoing headwinds from slower market demand and internal operational challenges.
Price Action: ADM shares are trading lower by 9.3% to $50.16 at last check Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/equities/24/11/41734875/palantirs-ai-gamble-pays-off-as-customer-revenue-from-single-customer-jumps-12x-in-under-8-month" target="_blank" rel="noreferrer noopener">Palantir&#8217;s AI Gamble Pays Off As Customer Revenue From Single Customer Jumps 12x In Under 8 Months — Alex Karp Quips: &#8216;We Should Just Go Home&#8217;</a></li>
</ul>

Earnings

Equities

Guidance

Markets

Movers

General

Archer-Daniels-Midland Stock Dips After Q3 Preliminary Results: Earnings Miss, Guidance Cut Amid Restatements

Lake Street analyst Eric Martinuzzi upgrades Brightcove (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCOV#NASDAQ">BCOV</a>) from Hold to Buy and raises the price target from $2.75 to $3.5.

Upgrades

BCOV

Lake Street Upgrades Brightcove to Buy, Raises Price Target to $3.5

Deutsche Bank analyst Ross Seymore maintains Astera Labs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALAB#NASDAQ">ALAB</a>) with a Buy and raises the price target from $60 to $100.

ALAB

Deutsche Bank Maintains Buy on Astera Labs, Raises Price Target to $100

Deutsche Bank analyst Brian Bedell maintains TPG (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TPG#NASDAQ">TPG</a>) with a Buy and raises the price target from $65 to $67.

Deutsche Bank Maintains Buy on TPG, Raises Price Target to $67

HC Wainwright &amp; Co. analyst Joseph Pantginis reiterates Krystal Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KRYS#NASDAQ">KRYS</a>) with a Buy and maintains $221 price target.

Reiteration

KRYS

HC Wainwright & Co. Reiterates Buy on Krystal Biotech, Maintains $221 Price Target

WIIM

TDUP

ThredUp shares are trading higher after the company reported better-than-expected Q3 EPS and sales and slightly raised its FY2024 sales guidance.

Deutsche Bank analyst Brian Bedell maintains Franklin Resources (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BEN#NYSE">BEN</a>) with a Hold and lowers the price target from $20 to $19.

Deutsche Bank Maintains Hold on Franklin Resources, Lowers Price Target to $19

Deutsche Bank analyst Brian Bedell maintains Brookfield Asset Mgmt (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BAM#NYSE">BAM</a>) with a Buy and raises the price target from $51 to $56.

Deutsche Bank Maintains Buy on Brookfield Asset Mgmt, Raises Price Target to $56

EGHT

8x8 shares are trading higher after the company reported better-than-expected Q2 EPS and sales.

Deutsche Bank analyst Brian Bedell maintains Affiliated Managers Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMG#NYSE">AMG</a>) with a Buy and lowers the price target from $219 to $204.

Deutsche Bank Maintains Buy on Affiliated Managers Group, Lowers Price Target to $204

HC Wainwright &amp; Co. analyst Douglas Tsao reiterates Disc Medicine (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IRON#NASDAQ">IRON</a>) with a Buy and maintains $70 price target.

IRON

HC Wainwright & Co. Reiterates Buy on Disc Medicine, Maintains $70 Price Target

Trio Petroleum Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TPET#NASDAQ">TPET</a>) shares are trading lower by 19% to 10 cents Tuesday morning after the company announced a <a href="https://www.benzinga.com/pressreleases/24/11/g41727117/trio-petroleum-corp-announces-reverse-stock-split">1-for-20 reverse stock split</a>, approved by its board and shareholders, to take effect on November 14. 
What To Know: This split will consolidate every 20 shares of common stock into 1 share, affecting all outstanding shares equally. Stockholders' ownership percentages will remain the same, though fractional shares will be rounded up. 
Adjustments will also be made to Trio's equity awards. The stock will begin trading on a post-split basis on November 15, under the same symbol (TPET) with a new CUSIP number.
Read Also: <a href="https://www.benzinga.com/news/earnings/24/11/41740288/us-stocks-set-for-cautious-start-as-investors-brace-for-volatility-on-election-day-expert-points-to">US Stocks Set For Cautious Start As Investors Brace For Volatility On Election Day: Expert Points To &#8216;Pretty Well Overall&#8217; Historical Performance</a>
According to data from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>, TPET has a 52-week high of $0.72 and a 52-week low of $0.08.

TPET

Why Trio Petroleum (TPET) Stock Is Trading Lower

HC Wainwright &amp; Co. analyst Emily Bodnar reiterates Atossa Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATOS#NASDAQ">ATOS</a>) with a Buy and maintains $6 price target.

ATOS

HC Wainwright & Co. Reiterates Buy on Atossa Therapeutics, Maintains $6 Price Target

Trio Petroleum shares are trading lower after the company announced a 1-for-20 reverse stock split.

<ul>
<li>DJT</li>
<li>PLTR</li>
<li>SMCI</li>
<li>LOT</li>
<li>TSLA</li>
<li>NVDA</li>
<li>HIMS</li>
<li>AI</li>
<li>LINE</li>
<li>BA</li>
</ul>
Data from <a href="https://swaggystocks.com/dashboard/wallstreetbets/ticker-sentiment">https://swaggystocks.com/dashboard/wallstreetbets/ticker-sentiment</a>
&nbsp;

Trading Ideas

Hims & Hers Health, Inc. Class A Common Stock

HIMS

LINE

NVDA

PLTR

SMCI

TSLA

Top 10 Trending Stocks On WallStreetBets As Of November 5, 2024 (Via Swaggy Stocks)

Biotech

LYEL

Lyell To Present Initial Clinical Data From Phase 1-2 Trial Of IMPT-314 CAR T-Cell Therapy For B-Cell Lymphoma At ASH 2024, Highlighting Fast Track Designation And Dual-Targeting CD19/CD20 Approach

Barclays analyst Alex Scott maintains Sun Life Financial (TSX:<a class="ticker" href="https://www.benzinga.com/stock/SLF#TSX">SLF</a>) with a Equal-Weight and raises the price target from C$76 to C$79.

TSX:SLF

Barclays Maintains Equal-Weight on Sun Life Financial, Raises Price Target to C$79

Bionomics Ltd &#8211; ADR (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNOX#NASDAQ">BNOX</a>) shares are trading higher by 177% to 53 cents Tuesday morning after the company announced it <a href="https://www.benzinga.com/pressreleases/24/11/g41727839/bionomics-receives-milestone-payment-of-aus-1m-from-carina-biotech-for-bnc101-partnered-legacy-onc">received a milestone payment</a> of AUD$1 million from Carina Biotech related to their partnered oncology program, BNC101.
What To Know: This payment aligns with their 2020 exclusive license agreement for BNC101, a monoclonal antibody targeting LGR5, a cancer stem cell antigen. 
Carina Biotech is developing an LGR5-targeted CAR-T therapy, CNA3103, for metastatic colorectal cancer, and Bionomics could earn up to AUD$118 million in further development, regulatory and commercial milestone payments if the therapy is fully developed and marketed.
Additionally, Bionomics is set to earn royalties on net sales and may receive a share of sublicensing revenue. Bionomics' CEO highlighted this payment as a testament to their research strength and noted the progress of their strategic partnership with Merck for an Alzheimer&#8217;s therapy, which could soon yield additional milestone payments.
Read Also: <a href="https://www.benzinga.com/news/earnings/24/11/41740288/us-stocks-set-for-cautious-start-as-investors-brace-for-volatility-on-election-day-expert-points-to">US Stocks Set For Cautious Start As Investors Brace For Volatility On Election Day: Expert Points To &#8216;Pretty Well Overall&#8217; Historical Performance</a>
<h2 class="wp-block-heading">How To Buy BNOX Stock</h2>
Besides going to a brokerage platform to purchase a share &#8211; or fractional share &#8211; of stock, you can also gain access to shares either by buying an exchange traded fund (ETF) that holds the stock itself, or by allocating yourself to a strategy in your 401(k) that would seek to acquire shares in a mutual fund or other instrument. 
For example, in Bionomics&#8217; case, it is in the Health Care sector. An ETF will likely hold shares in many liquid and large companies that help track that sector, allowing an investor to gain exposure to the trends within that segment.
According to data from&nbsp;<a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>, BNOX has a 52-week high of $2.84 and a 52-week low of $0.18.

BNOX

Why Bionomics (BNOX) Stock Is Up 100% Today

REQORSA Modulates In Vivo Immune Responses Against Cancers
AUSTIN, Texas, Nov. 5, 2024 /PRNewswire/ -- <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4294293-1&amp;h=152405195&amp;u=https%3A%2F%2Fwww.genprex.com%2F&amp;a=Genprex%2C+Inc.">Genprex, Inc.</a> ("Genprex" or the "Company") (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/gnpx#NASDAQ">GNPX</a>), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that its research collaborators at Meharry Medical College will present a poster detailing positive preclinical data from a study of the Company's lead drug candidate, Reqorsa&#xAE; Gene Therapy (quaratusugene ozeplasmid)&nbsp;evaluating TUSC2's role in modulating immune responses in cancer. The poster will be presented at the 39th Annual Society for Immunotherapy of Cancer Meeting being held November 6-10, 2024 in Houston, Texas.

Penny Stocks

GNPX

Genprex Collaborators Present Preclinical Data On Reqorsa Gene Therapy At The Society For Immunotherapy Of Cancer 2024 Annual Meeting; REQORSA Modulates In Vivo Immune Responses Against Cancers

Michael Higgins, an analyst from Ladenburg Thalmann & Co., maintained the Buy rating on BiomX (PHGE – Research Report). The associated price target...

BiomX Buy Rating Affirmed on Clinical Progress and Strategic Acquisition

BiomX (PHGE) has issued an announcement. BiomX, Inc. has been notified by NYSE American that it's not meeting the required listing standards due to...

BiomX Faces NYSE Delisting Over Equity Deficiency

An update from BiomX (PHGE) is now available. At the Annual Meeting, shareholders of the Company decisively voted to increase the authorized shares...

BiomX Shareholders Approve Expansion and Governance Changes

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
BiomX (NYSEMKT:<a href="https://investorplace.com/stock-quotes/phge-stock-quote/">PHGE</a>) just reported results for the second quarter of 2024.<ul><li>BiomX reported earnings per share of -7 cents.</li><li>The company did not report any revenue for the quarter.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/earning-results/2024/08/phge-stock-earnings-biomx-for-q2-of-2024/">PHGE Stock Earnings: BiomX Reported Results for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

PHGE Stock Earnings: BiomX Reported Results for Q2 2024

BiomX to implement a reverse stock split

BiomX GAAP EPS of -$0.07

BiomX Inc. (PHGE) Q2 2024 Earnings Call Transcript

Analyst Michael Higgins of Ladenburg Thalmann & Co. maintained a Buy rating on BiomX (PHGE – Research Report), retaining the price target of $2.00....

BiomX Buy Rating Affirmed by Analyst Michael Higgins on Strong Clinical Progress and Strategic Acquisitions

In a report released today, Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on BiomX (PHGE – Research Report), with a price target of...

Buy Rating for BiomX: Solid Financials and Promising Clinical Pipeline Signal Strong Future Performance

BiomX ( ($PHGE) ) has issued an announcement. BiomX Inc., a clinical-stage biotechnology company, actively communicates with investors and provides...

Comments

BiomX

BiomX (PHGE) Opzioni

No option chain data available. Please try again later

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO